OCT 29, 2021 11:00 AM PDT

Common Antidepressant Reduces COVID-19 Hospitalizations by 30%

WRITTEN BY: Annie Lennon

The widely-available antidepressant fluvoxamine reduces COVID-19 hospitalizations by 30%. The corresponding study was published in The Lancet Global Health

Fluvoxamine has a well-known safety profile and has been used as an antidepressant since the 1990’s for various conditions. Due to its anti-inflammatory properties, scientists had suspected since the beginning of the pandemic that it may have utility in treating the cytokine storms, an excessive and deadly immune response that presents in severe cases of COVID-19. 

In 2020, a study was published by researchers from the Washington University School of Medicine concerning the drug. In a placebo-controlled trial involving 152 patients with COVID-19, they found that patients taking fluoxetine ‘did not develop serious breathing difficulties or require hospitalization for problems with lung function’.  

The present study echoes and expands on these results. Under placebo-controlled, randomized conditions, the researchers split 1497 patients with COVID-19 into two treatment arms: one receiving 100 mg of fluvoxamine twice daily for 10 days or a placebo. 

The average age of participants was 50 years old, and 58% were female. All were at a high risk of developing severe symptoms of the disease. Both groups were tracked for 28 days following the trial to determine the effect of the drug. 

The researchers found that patients receiving fluvoxamine were hospitalized 30% less than those taking placebos. They also note, however, that of the 741 patients receiving fluoxetine, 84 discontinued treatment due to intolerability, while 64 stopped taking the placebo also due to intolerability. 

“Fluvoxamine is, so far, the only treatment that if administered early, can prevent COVID-19 from becoming a life-threatening illness. It could be one of our most powerful weapons against the virus and its effectiveness is one of the most important discoveries we have made since the pandemic began,” said Edward Mills, professor of McMaster's Department of Health Research Methods, Evidence, and Impact and co-principal investigator for the TOGETHER Trial, a group of clinical trials aiming to test potential COVID-19 treatments in community settings.

He added that as fluvoxamine costs around $4 per 10-day course, it may be particularly beneficial for poorer countries with low rates of vaccination, and who lack access to other COVID-19 therapy options. 

 

Sources: The Lancet Global Health, LabRoots, News Medical

 

About the Author
Other
Annie Lennon is a writer whose work also appears in Medical News Today, Psych Central, Psychology Today, and other outlets. When she's not writing, she is COO of Xeurix, an HR startup that assesses jobfit from gamified workplace simulations.
You May Also Like
DEC 07, 2022
Drug Discovery & Development
Mucus Eating Microbe Contributes to Major Cancer Treatment Complication
Mucus Eating Microbe Contributes to Major Cancer Treatment Complication
  Akkermansia muciniphila loves to degrade mucin, a molecule found in mucus. We’ve identified this and other ...
DEC 18, 2022
Drug Discovery & Development
Activated Vitamin D3 May Protect Against Arsenic in Drinking Water
Activated Vitamin D3 May Protect Against Arsenic in Drinking Water
Activated vitamin D3 may protect against various conditions- including skin cancer- that arise after drinking arsenic-co ...
DEC 28, 2022
Health & Medicine
New weapon against antimicrobial resistance strikes down bacterial cell walls
New weapon against antimicrobial resistance strikes down bacterial cell walls
For millennia the arms race between bacteria and animals was fought through mutations and evolution. As modern bacteria ...
JAN 19, 2023
Drug Discovery & Development
Introducing TruCytes™: The Ready-to-Use Immunophenotyping Control for Cell Therapy, Flow Cytometry and Beyond
Introducing TruCytes™: The Ready-to-Use Immunophenotyping Control for Cell Therapy, Flow Cytometry and Beyond
Are you a cell biologist, immunologist, or flow cytometrist? If so, you know how challenging it is to find quality contr ...
JAN 23, 2023
Neuroscience
Tau tangles unravel when these three genes are silenced
Tau tangles unravel when these three genes are silenced
By controling the activity of an enzyme called CHIP, three proteins regulate tau. Now the genes for these three trouble ...
JAN 28, 2023
Drug Discovery & Development
Parkinson's Drug May Reduce Brain Inflammation from Depression
Parkinson's Drug May Reduce Brain Inflammation from Depression
Levodopa, a drug used to increase dopamine levels in people with Parkinson’s disease, may also reverse the effects ...
Loading Comments...